RIL
SRPT icon

Rothschild Investment LLC’s Sarepta Therapeutics SRPT Stock Holding History

Rothschild Investment LLC’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.4K Sell
4,921
-1,258
-20% -$23.8K ﹤0.01% 1091
2026
Q1 		$134K Sell
6,179
-3,046
-33% -$59K 0.01% 796
2025
Q4 		$199K Buy
9,225
+7,936
+616% +$167K 0.01% 624
2025
Q3 		$24.8K Buy
+1,289
New +$23K ﹤0.01% 1180

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

Rothschild Investment LLC's SRPT Position: Q2 2026 in Review

Rothschild Investment LLC reduced its Sarepta Therapeutics (SRPT) stake by 20% in Q2 2026, selling an estimated $23.8K and leaving 4,921 shares worth $88.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1091.

Rothschild Investment LLC first reported a position in SRPT in Q3 2025 and has held it in 4 quarters since. The position peaked at $199K in Q4 2025. 121 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Rothschild Investment LLC held 4,921 shares of Sarepta Therapeutics worth $88.4K as of Q2 2026.
  • Rothschild Investment LLC sold 1,258 Sarepta Therapeutics shares in Q2 2026, an estimated $23.8K.
  • Sarepta Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #1091 holding.
  • Rothschild Investment LLC first reported a position in Sarepta Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Rothschild Investment LLC's Sarepta Therapeutics position peaked at $199K in Q4 2025.
  • 121 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.